S&P 500   4,550.58
DOW   35,430.42
QQQ   389.81
How to trade penny stocks: A step-by-step guide
Laser breakthrough could send stock soaring 2,467% (Ad)
These are the top sectors for blue chip growth in 2024
MercadoLibre up 28% as Latin American ecommerce poised for growth
BREAKING: Tiny biotech successfully treats blindness (Ad)
The 4 highest-shorted large-cap stocks
The JD.com train is getting ready to leave the station again
BREAKING: Tiny biotech successfully treats blindness (Ad)
3 stocking stuffers you can buy for yourself
Argentina's libertarian president-elect picks a former Central Bank chief as his economy minister
S&P 500   4,550.58
DOW   35,430.42
QQQ   389.81
How to trade penny stocks: A step-by-step guide
Laser breakthrough could send stock soaring 2,467% (Ad)
These are the top sectors for blue chip growth in 2024
MercadoLibre up 28% as Latin American ecommerce poised for growth
BREAKING: Tiny biotech successfully treats blindness (Ad)
The 4 highest-shorted large-cap stocks
The JD.com train is getting ready to leave the station again
BREAKING: Tiny biotech successfully treats blindness (Ad)
3 stocking stuffers you can buy for yourself
Argentina's libertarian president-elect picks a former Central Bank chief as his economy minister
S&P 500   4,550.58
DOW   35,430.42
QQQ   389.81
How to trade penny stocks: A step-by-step guide
Laser breakthrough could send stock soaring 2,467% (Ad)
These are the top sectors for blue chip growth in 2024
MercadoLibre up 28% as Latin American ecommerce poised for growth
BREAKING: Tiny biotech successfully treats blindness (Ad)
The 4 highest-shorted large-cap stocks
The JD.com train is getting ready to leave the station again
BREAKING: Tiny biotech successfully treats blindness (Ad)
3 stocking stuffers you can buy for yourself
Argentina's libertarian president-elect picks a former Central Bank chief as his economy minister
S&P 500   4,550.58
DOW   35,430.42
QQQ   389.81
How to trade penny stocks: A step-by-step guide
Laser breakthrough could send stock soaring 2,467% (Ad)
These are the top sectors for blue chip growth in 2024
MercadoLibre up 28% as Latin American ecommerce poised for growth
BREAKING: Tiny biotech successfully treats blindness (Ad)
The 4 highest-shorted large-cap stocks
The JD.com train is getting ready to leave the station again
BREAKING: Tiny biotech successfully treats blindness (Ad)
3 stocking stuffers you can buy for yourself
Argentina's libertarian president-elect picks a former Central Bank chief as his economy minister

Monopar Therapeutics Stock Price, News & Analysis (NASDAQ:MNPR)

$0.30
+0.01 (+3.39%)
(As of 11/29/2023 ET)
Compare
Today's Range
$0.29
$0.33
50-Day Range
$0.29
$0.60
52-Week Range
$0.27
$3.82
Volume
155,473 shs
Average Volume
2.96 million shs
Market Capitalization
$4.53 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.00

Monopar Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
4,167.9% Upside
$13.00 Price Target
Short Interest
Healthy
3.14% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.43mentions of Monopar Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.67) to ($0.68) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.06 out of 5 stars


MNPR stock logo

About Monopar Therapeutics Stock (NASDAQ:MNPR)

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

MNPR Stock Price History

MNPR Stock News Headlines

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Expert Ratings for Monopar Therapeutics
Monopar Therapeutics Inc (MNPR) Gets a Buy from H.C. Wainwright
10-Q: MONOPAR THERAPEUTICS
See More Headlines
Receive MNPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Monopar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/12/2021
Today
11/30/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/28/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MNPR
Fax
N/A
Employees
11
Year Founded
2014

Price Target and Rating

Average Stock Price Target
$13.00
High Stock Price Target
$24.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+4,167.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-10,520,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.44 per share

Miscellaneous

Free Float
8,682,000
Market Cap
$4.53 million
Optionable
Not Optionable
Beta
0.95

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for December 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Chandler D. Robinson M.B.A. (Age 39)
    M.D., M.Sc., MBA, MSc, Co-Founder, CEO, President & Director
    Comp: $708.12k
  • Ms. Kim R. Tsuchimoto CPA (Age 60)
    CFO, Secretary, Treasurer & Director
    Comp: $350.55k
  • Mr. Andrew J. Cittadine M.B.A. (Age 51)
    Chief Operating Officer
    Comp: $390.41k
  • Dr. Patrice P. Rioux M.D. (Age 72)
    Ph.D., Acting Chief Medical Officer














MNPR Stock Analysis - Frequently Asked Questions

Should I buy or sell Monopar Therapeutics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Monopar Therapeutics in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MNPR shares.
View MNPR analyst ratings
or view top-rated stocks.

What is Monopar Therapeutics' stock price target for 2024?

4 equities research analysts have issued twelve-month price objectives for Monopar Therapeutics' stock. Their MNPR share price targets range from $2.00 to $24.00. On average, they predict the company's share price to reach $13.00 in the next year. This suggests a possible upside of 4,167.9% from the stock's current price.
View analysts price targets for MNPR
or view top-rated stocks among Wall Street analysts.

How have MNPR shares performed in 2023?

Monopar Therapeutics' stock was trading at $2.37 on January 1st, 2023. Since then, MNPR shares have decreased by 87.1% and is now trading at $0.3046.
View the best growth stocks for 2023 here
.

Are investors shorting Monopar Therapeutics?

Monopar Therapeutics saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 187,800 shares, an increase of 277.9% from the October 31st total of 49,700 shares. Based on an average trading volume of 923,400 shares, the short-interest ratio is presently 0.2 days. Approximately 3.1% of the shares of the stock are sold short.
View Monopar Therapeutics' Short Interest
.

When is Monopar Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our MNPR earnings forecast
.

How were Monopar Therapeutics' earnings last quarter?

Monopar Therapeutics Inc. (NASDAQ:MNPR) posted its quarterly earnings results on Friday, November, 12th. The company reported ($0.20) earnings per share for the quarter, topping analysts' consensus estimates of ($0.22) by $0.02.

What other stocks do shareholders of Monopar Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Monopar Therapeutics investors own include Entasis Therapeutics (ETTX), Fulcrum Therapeutics (FULC), Sorrento Therapeutics (SRNE), Akero Therapeutics (AKRO), Chimerix (CMRX), Trevena (TRVN), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD) and Aquestive Therapeutics (AQST).

When did Monopar Therapeutics IPO?

(MNPR) raised $9 million in an initial public offering on Thursday, December 19th 2019. The company issued 1,100,000 shares at $8.00 per share. JonesTrading served as the underwriter for the IPO and Arcadia Securities was co-manager.

Who are Monopar Therapeutics' major shareholders?

Monopar Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Windsor Advisory Group LLC (0.64%). Insiders that own company stock include Andrew Cittadine and Tactic Pharma Llc.
View institutional ownership trends
.

How do I buy shares of Monopar Therapeutics?

Shares of MNPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Does Monopar Therapeutics have any subsidiaries?
The following companies are subsidiares of Monopar Therapeutics: Monopar Therapeutics Pty Ltd, and Monopar Therapeutics SARL.
Read More
This page (NASDAQ:MNPR) was last updated on 11/30/2023 by MarketBeat.com Staff

My Account -